Alaunos Therapeutics (TCRT) Receivables - Other (2020 - 2021)
Alaunos Therapeutics' (TCRT) quarterly Receivables - Other came in at $1.1 million in Q3 2021, down 85.53% on a QoQ basis from $7.6 million in Q2 2021.
Alaunos Therapeutics (TCRT) Receivables - Other (2020 - 2021) Analysis & Trends
Alaunos Therapeutics (TCRT) has 2 years of Receivables - Other data on file, last reported at $1.1 million in Q3 2021.
- Quarterly Receivables - Other changed N/A year-over-year to $1.1 million in Q3 2021, while the trailing twelve-month figure through Sep 2021 was $1.1 million (changed N/A YoY) and the FY2020 annual result came in at $4.7 million, changed N/A from the prior year.
- Receivables - Other slipped to $1.1 million in Q3 2021, from $7.6 million in the prior quarter.
- In the past five years, Receivables - Other ranged from a high of $7.6 million in Q2 2021 to a low of $1.1 million in Q3 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Alaunos Therapeutics | 4.28 Mn | 4.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | 1.10 Mn |
| Sep 30, 2021 | 1.10 Mn |
| Jun 30, 2021 | 7.60 Mn |
| Jun 30, 2021 | 7.60 Mn |
| Dec 31, 2020 | 4.70 Mn |
| Dec 31, 2020 | 4.70 Mn |